Amarin Corp Plc\Uk
$5.60B- Market cap
- $5.73B
- Debt
- +$177.39M
- Cash
- −$302.59M
Capital structure 97% equity / 3% debt · EV / Revenue 26.21x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt cap
Decision snapshot: AMRN stock price at premium vs ZS $13.63 current versus $4.25 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZS's multiple
Implied fair value · at AMRN's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMRN FY 2025 (ended Dec 31, 2025) · ZS FY 2026 (ended Jul 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 97% equity / 3% debt · EV / Revenue 26.21x
Capital structure 94% equity / 6% debt · EV / Revenue 8.55x · EV / EBITDA 262.32x
ZS carries the larger enterprise value at $28.66B against $5.60B; ZS trades on the lower EV / Revenue multiple (8.55x vs 26.21x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AMARIN CORP PLC\UK · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Zscaler Inc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.39x
0.73x
Net debt / EBITDA
Leverage against operating earnings
3.79x
8.93x
Cash and equivalents
Liquid reserves on the balance sheet
$302.59M
$928.35M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
Palo Alto Networks Inc
AMRN vs PANW
CrowdStrike Holdings, Inc.
AMRN vs CRWD
Okta, Inc.
AMRN vs OKTA
Cloudflare, Inc.
AMRN vs NET
Fortinet, Inc.
AMRN vs FTNT
$177.39M
$1.90B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe AMRN can reaccelerate revenue and improve margins from -6.5% growth and -23.5% operating margin toward a ZS-like operating trajectory, then AMRN could justify a higher multiple; otherwise, the current P/S-based valuation suggests the stock remains expensive relative to its fundamentals.
AMRN's current price of $16.37 compares with an implied price of $4.59 from the P/S-based comparison, indicating a -72.0% downside on this framework. However, the stock also sits inside its historical band of $14.73 to $18.01, which suggests the market is not pricing it far outside recent norms.
Supporting Metrics